Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2023-09-18 Proxy Solicitation & In…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Extraordinary General Meeting' (주주총회소집공고) for PharmAbcine. It details the agenda for the meeting, specifically the appointment of directors (사내이사 and 사외이사), and includes candidate profiles, board recommendations, and voting procedures. This type of document is sent to shareholders to provide information and request votes for an upcoming meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2023-09-18 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by PharmAbcine. It provides shareholders with information regarding an upcoming Extraordinary General Meeting, including the agenda (election of directors), proxy solicitation details, and the rationale for the meeting. This falls directly under the definition of Proxy Solicitation & Information Statement (PSI).
2023-09-18 Korean
[기재정정]주주총회소집결의(임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from the company 'PharmAbcine' (파멥신) regarding an amendment to a previous notice of an Extraordinary General Meeting (EGM). It details changes to the meeting date and corrections to director candidate information. Since this is a formal regulatory announcement regarding the logistics and agenda of a shareholder meeting, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders regarding upcoming voting items.
2023-09-18 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정)(진행성 또는 전이성 고형암 환자에서 PMC-309(Anti-VISTA)의 안전성, 내약성 및 약동학을 평가하기 위한 최초 인간 투여, 공개 1a/1b상 임상시험계획 승인(HREC))
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (PharmAbcine) regarding the approval of a clinical trial (Phase 1a/1b for PMC-309). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a formal regulatory disclosure of a material event, it is classified as a Regulatory Filing (RNS).
2023-09-15 Korean
소송등의제기ㆍ신청(경영권분쟁소송)(주주총회소집허가)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (PharmaAb) regarding a 'Lawsuit/Legal Proceeding' (소송 등의 제기ㆍ신청) specifically concerning a management dispute (경영권 분쟁 소송) and a request for permission to convene an extraordinary general meeting of shareholders. Since the document details a legal action/lawsuit involving the company, it falls under the 'Legal Proceedings Report' category.
2023-09-15 Korean
[기재정정]주주총회소집결의(임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from a Korean company (PharmAbcine) regarding the 'Convocation of an Extraordinary General Meeting' (주주총회소집결의). It details changes to the agenda, specifically the appointment of new directors and outside directors. This type of document is a formal notice to shareholders regarding the logistics and agenda of an upcoming meeting, which falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to vote on the proposed board changes.
2023-09-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.